$GENB

Several biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.

Generate Biomedicines (GENB) reported Q2 2026 revenue of $6.3M, down from $10.1M YoY, with net loss widening to $67.3M. R&D and G&A expenses rose, driven by Phase 3 asthma trials. Cash reserves total $457.4M. GENB advanced clinical trials for asthma, COPD, and oncology treatments, with Novartis progressing a biologic using its AI platform. Shares rose 19.02%.

Generate Biomedicines, Inc. (GENB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase

Nvidia (NVDA) said AI’s “most profound impact” will be in life sciences and announced an AI co-innovation lab with Eli Lilly, targeting up to $1 billion over five years. Nvidia’s May 13F showed it owned 833,000+ shares of Generate Biomedicines (GENB), valued at about $10.4 million as of Q1 end. The article links Nvidia’s AI push to its biotech investment.

Nvidia, through its venture arm NVentures, owns 833,325 shares of Generate Biomedicines (NASDAQ: GENB), according to the article. The stake totals about $13 million, and Generate Biomedicines is a pre-profit biotech developing an AI platform for virtual drug testing; four candidates are in its pipeline, including one in Phase 3 for severe asthma (GB-0895). The piece cites estimates that drug development can take 10–15 years and about $2.6 billion per approved medicine.

Reuters (May 27) reported Biohub, founded by Meta CEO Mark Zuckerberg and Priscilla Chan, developed an open-source global protein-biology model using fourth-generation evolutionary scale modeling (ESM) to speed drug discovery. Biohub said it will run via Biohub.ai and partners like AWS Bio Discovery, with computing credits, and expects broader lab use. The article also lists hedge-fund “AI drug discovery” holdings, including SOPHiA Genetics’ proposed MSK precision-oncology JV and Generate Biomed